BLK Inhibitors
1 drugsAbout BLK
BLK (B Lymphoid Kinase) is an intracellular tyrosine kinase in the Src family, involved in B-cell receptor signaling and development. It plays a role in cellular signaling pathways, making it a potential therapeutic target.
Currently, there is no genetic evidence directly linking BLK to specific diseases. However, its role in B-cell signaling suggests potential for therapeutic intervention by modulating cellular processes.
BLK is targeted by one FDA-approved small molecule drug, TAGRISSO (AstraZeneca), approved in 2015. This drug has applications beyond common disease areas, classified as 'Other'.
Top BLK Drugs
AstraZeneca is the only company with an approved drug targeting BLK.
The limited competitive landscape suggests a high barrier to entry or untapped potential for new entrants.
BLK Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets BLK, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide differentiation and IP opportunities.
BLK Clinical Trials 176 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on BLK. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 61 | 17 | 9 | 35 | 65% |
| Phase 2 | 85 | 18 | 5 | 62 | 78% |
| Phase 3 | 28 | 0 | 2 | 26 | 0% |
| Phase 4 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved BLK drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting BLK. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
BLK Drug Approval Timeline (2015 - 2015)
Adjuvant therapy after tumor resection in adult patients ...
The first and only drug targeting BLK, TAGRISSO, was approved in 2015.
The lack of recent approvals indicates either limited therapeutic potential or an opportunity for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 109 (42 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on BLK. A trial counts if an approved drug acting on BLK is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.